MX381102B - Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. - Google Patents
Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado.Info
- Publication number
- MX381102B MX381102B MX2016001384A MX2016001384A MX381102B MX 381102 B MX381102 B MX 381102B MX 2016001384 A MX2016001384 A MX 2016001384A MX 2016001384 A MX2016001384 A MX 2016001384A MX 381102 B MX381102 B MX 381102B
- Authority
- MX
- Mexico
- Prior art keywords
- benralizumab
- asthma
- treatment
- expiratory volume
- forced expiratory
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Biomedical Technology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Endocrinology (AREA)
Abstract
La presente invención se refiere a una cantidad efectiva de benralizumab para usarse en un método para tratar asma al aumentar un volumen espiratorio forzado en un segundo (FEV1) en un paciente asmático, en donde la administración aumenta el FEV1 del paciente, en donde el benralizumab está adaptado para ser administrable a una dosis de 30 mg una vez cada cuatro semanas durante doce semanas y después una vez cada ocho semanas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361864948P | 2013-08-12 | 2013-08-12 | |
| PCT/US2014/050119 WO2015023507A2 (en) | 2013-08-12 | 2014-08-07 | Methods for increasing forced expiratory volume in asthmatics using benralizumab |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016001384A MX2016001384A (es) | 2016-08-03 |
| MX381102B true MX381102B (es) | 2025-03-12 |
Family
ID=52448838
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016001384A MX381102B (es) | 2013-08-12 | 2014-08-07 | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. |
| MX2021003826A MX2021003826A (es) | 2013-08-12 | 2016-01-29 | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021003826A MX2021003826A (es) | 2013-08-12 | 2016-01-29 | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US9441046B2 (es) |
| EP (5) | EP3033104B1 (es) |
| JP (4) | JP6746496B2 (es) |
| KR (1) | KR102337599B1 (es) |
| CN (2) | CN105451769A (es) |
| AU (2) | AU2014306959B2 (es) |
| BR (1) | BR112016002317A8 (es) |
| CA (1) | CA2917603C (es) |
| CY (2) | CY1122033T1 (es) |
| DK (2) | DK3520811T3 (es) |
| ES (2) | ES2866426T3 (es) |
| HK (1) | HK1222559A1 (es) |
| HR (2) | HRP20190920T1 (es) |
| HU (2) | HUE053627T2 (es) |
| LT (2) | LT3033104T (es) |
| ME (1) | ME03403B (es) |
| MX (2) | MX381102B (es) |
| PL (2) | PL3520811T3 (es) |
| PT (2) | PT3033104T (es) |
| RS (2) | RS58711B1 (es) |
| RU (1) | RU2703568C2 (es) |
| SG (1) | SG11201600483QA (es) |
| SI (2) | SI3520811T1 (es) |
| SM (2) | SMT201900311T1 (es) |
| TR (1) | TR201907907T4 (es) |
| WO (1) | WO2015023507A2 (es) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2918105C (en) * | 2013-08-12 | 2023-02-28 | Medimmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| BR112016002462A8 (pt) * | 2013-08-12 | 2018-06-12 | Medimmune Llc | Métodos para melhorar os sintomas da asma usando benralizumabe |
| SG10201807318RA (en) * | 2013-10-15 | 2018-09-27 | Astrazeneca Ab | Methods for treating chronic obstructive pulmonary disease using benralizumab |
| LT3060229T (lt) * | 2013-10-24 | 2021-09-27 | Astrazeneca Ab | Stabilios vandeninės antikūno vaistinės formos |
| TW202110479A (zh) * | 2019-05-16 | 2021-03-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療增強型患者群體慢性阻塞性肺病之方法 |
| TW202126688A (zh) * | 2019-09-27 | 2021-07-16 | 瑞典商阿斯特捷利康公司 | 使用貝那利珠單抗治療遲發性氣喘之方法 |
| TW202214692A (zh) * | 2020-06-05 | 2022-04-16 | 瑞典商阿斯特捷利康公司 | 治療患有鼻瘜肉的患者的重度氣喘之方法 |
| WO2026053166A1 (en) * | 2024-09-06 | 2026-03-12 | Medimmune Limited | Anti-il5r-alpha treatment for acute exacerbations of asthma and copd |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2233974T3 (es) | 1995-09-11 | 2005-06-16 | Kyowa Hakko Kogyo Co., Ltd. | Anticuerpo contra la cadena alfa del receptor de la interleucina 5 humana. |
| US6746839B1 (en) * | 1998-01-12 | 2004-06-08 | Interleukin Genetics, Inc. | Diagnostics and therapeutics for an obstructive airway disease |
| EP2275540B1 (en) | 1999-04-09 | 2016-03-23 | Kyowa Hakko Kirin Co., Ltd. | Method for controlling the activity of immunologically functional molecule |
| WO2001060405A1 (en) | 2000-02-15 | 2001-08-23 | Kyowa Hakko Kogyo Co., Ltd. | Eosinophil-specific apoptosis inducer |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| US8093357B2 (en) | 2002-03-01 | 2012-01-10 | Xencor, Inc. | Optimized Fc variants and methods for their generation |
| AU2004279740A1 (en) | 2003-10-08 | 2005-04-21 | Kyowa Hakko Kirin Co., Ltd. | Antibody composition specifically binding to IL-5 receptor |
| US20060014680A1 (en) | 2004-07-13 | 2006-01-19 | Caiding Xu | Peptides and compounds that bind to the IL-5 receptor |
| DK1931709T3 (en) | 2005-10-03 | 2017-03-13 | Xencor Inc | FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES |
| PT3072525T (pt) * | 2007-05-14 | 2018-04-20 | Astrazeneca Ab | Métodos para reduzir os níveis de basófilos |
| RU2383345C1 (ru) * | 2008-08-07 | 2010-03-10 | Государственное образовательное учреждение высшего профессионального образования "Нижегородская государственная медицинская академия Росздрава" (ГОУ ВПО "НИЖГМА РОСЗДРАВА") | Способ лечения больных бронхиальной астмой |
| KR101615420B1 (ko) * | 2010-12-16 | 2016-04-26 | 제넨테크, 인크. | Th2 억제에 관한 진단 및 치료 |
| CN102544908B (zh) | 2010-12-17 | 2016-01-06 | 富士康(昆山)电脑接插件有限公司 | 电连接器组件及插头连接器 |
| WO2012158954A1 (en) | 2011-05-18 | 2012-11-22 | Medimmune, Llc | Methods of diagnosing and treating pulmonary diseases or disorders |
| CN104039352A (zh) | 2011-11-01 | 2014-09-10 | 米迪缪尼有限公司 | 用于降低哮喘急性恶化的频率和严重性的方法 |
| CA2918105C (en) * | 2013-08-12 | 2023-02-28 | Medimmune, Llc | Methods for reducing exacerbation rates of asthma using benralizumab |
| BR112016002462A8 (pt) * | 2013-08-12 | 2018-06-12 | Medimmune Llc | Métodos para melhorar os sintomas da asma usando benralizumabe |
-
2014
- 2014-08-07 SM SM20190311T patent/SMT201900311T1/it unknown
- 2014-08-07 LT LTEP14836725.3T patent/LT3033104T/lt unknown
- 2014-08-07 WO PCT/US2014/050119 patent/WO2015023507A2/en not_active Ceased
- 2014-08-07 SI SI201431795T patent/SI3520811T1/sl unknown
- 2014-08-07 EP EP14836725.3A patent/EP3033104B1/en active Active
- 2014-08-07 EP EP19158446.5A patent/EP3520811B1/en active Active
- 2014-08-07 SI SI201431191T patent/SI3033104T1/sl unknown
- 2014-08-07 EP EP25191983.3A patent/EP4636400A3/en active Pending
- 2014-08-07 HU HUE19158446A patent/HUE053627T2/hu unknown
- 2014-08-07 ES ES19158446T patent/ES2866426T3/es active Active
- 2014-08-07 PL PL19158446T patent/PL3520811T3/pl unknown
- 2014-08-07 RS RS20190556A patent/RS58711B1/sr unknown
- 2014-08-07 MX MX2016001384A patent/MX381102B/es unknown
- 2014-08-07 EP EP20208316.8A patent/EP3875487A1/en not_active Withdrawn
- 2014-08-07 ES ES14836725T patent/ES2733602T3/es active Active
- 2014-08-07 HK HK16110776.1A patent/HK1222559A1/zh unknown
- 2014-08-07 DK DK19158446.5T patent/DK3520811T3/da active
- 2014-08-07 RS RS20210305A patent/RS61565B1/sr unknown
- 2014-08-07 HR HRP20190920TT patent/HRP20190920T1/hr unknown
- 2014-08-07 AU AU2014306959A patent/AU2014306959B2/en active Active
- 2014-08-07 LT LTEP19158446.5T patent/LT3520811T/lt unknown
- 2014-08-07 TR TR2019/07907T patent/TR201907907T4/tr unknown
- 2014-08-07 CN CN201480045047.8A patent/CN105451769A/zh active Pending
- 2014-08-07 ME MEP-2019-137A patent/ME03403B/me unknown
- 2014-08-07 PT PT14836725T patent/PT3033104T/pt unknown
- 2014-08-07 CA CA2917603A patent/CA2917603C/en active Active
- 2014-08-07 DK DK14836725.3T patent/DK3033104T3/da active
- 2014-08-07 RU RU2016108809A patent/RU2703568C2/ru active
- 2014-08-07 JP JP2016534615A patent/JP6746496B2/ja active Active
- 2014-08-07 HU HUE14836725A patent/HUE043497T2/hu unknown
- 2014-08-07 PL PL14836725T patent/PL3033104T3/pl unknown
- 2014-08-07 BR BR112016002317A patent/BR112016002317A8/pt not_active Application Discontinuation
- 2014-08-07 EP EP25150773.7A patent/EP4579236A3/en not_active Withdrawn
- 2014-08-07 KR KR1020167006576A patent/KR102337599B1/ko active Active
- 2014-08-07 SM SM20210152T patent/SMT202100152T1/it unknown
- 2014-08-07 SG SG11201600483QA patent/SG11201600483QA/en unknown
- 2014-08-07 US US14/454,138 patent/US9441046B2/en active Active
- 2014-08-07 PT PT191584465T patent/PT3520811T/pt unknown
- 2014-08-07 CN CN202010450690.6A patent/CN111588849A/zh active Pending
-
2016
- 2016-01-29 MX MX2021003826A patent/MX2021003826A/es unknown
-
2019
- 2019-07-03 CY CY20191100700T patent/CY1122033T1/el unknown
-
2020
- 2020-02-21 AU AU2020201277A patent/AU2020201277A1/en not_active Abandoned
- 2020-04-03 JP JP2020067766A patent/JP2020125304A/ja not_active Withdrawn
-
2021
- 2021-03-10 HR HRP20210406TT patent/HRP20210406T1/hr unknown
- 2021-03-24 CY CY20211100261T patent/CY1124399T1/el unknown
-
2022
- 2022-06-07 JP JP2022092222A patent/JP2022120010A/ja active Pending
-
2024
- 2024-07-05 JP JP2024108997A patent/JP7864776B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2024013963A (es) | Un antagonista de il-4r util para el tratamiento o la prevencion del asma | |
| CY1122186T1 (el) | Μεθοδοι θεραπειας καρκινου | |
| JOP20180104B1 (ar) | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس | |
| CY1123490T1 (el) | Συνθεσεις που προερχονται απο χιτοζανη | |
| CY1116987T1 (el) | Συμπυκνωμενα ιμιδαζολυλιμιδαζολια ως αντιϊικες ενωσεις | |
| EA201690513A1 (ru) | Комбинация ингибитора mek и ингибитора erk для применения в лечении гиперпролиферативных заболеваний | |
| PY1337526A (es) | Métodos para tratar o prevenir asma administrando un antagonista de IL-4R. | |
| EA201591591A1 (ru) | Соединения карбазола, применяемые в качестве ингибиторов бромодомена | |
| EA201790273A1 (ru) | Флагеллиновые композиции и их применение | |
| EA201690406A1 (ru) | Селективные ингибиторы grp94 и способы их применения | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| BR112015022047A2 (pt) | métodos para tratar câncer de bexiga | |
| MX2021003826A (es) | Benralizumab para usarse en el tratamiento de asma incrementando el volumen espiratorio forzado. | |
| EA201790630A1 (ru) | Способы получения рибозидов | |
| EA201591406A1 (ru) | C-19 модифицированные тритерпеноиды с ингибиторной активностью созревания вич | |
| EA201690561A1 (ru) | Пептидилнитрильные соединения в качестве ингибиторов дипептидилпептидазы i | |
| EA201600434A1 (ru) | Применение производных бензимидазолпролина | |
| EA201692481A1 (ru) | Комбинация, содержащая глюкокортикоид и edo-s101 | |
| MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. | |
| MX376183B (es) | Composiciones para el tratamiento de rosacea. | |
| MX2016001195A (es) | Metodos para mejorar sintomas de asma mediante el uso de benralizumab. | |
| EA201692518A2 (ru) | Способы улучшения производительности миокарда у пациентов после операции фонтена с применением композиций уденафила | |
| EA201500736A1 (ru) | Пиразолилкарбоксамиды i в качестве ингибиторов crac каналов | |
| EA201491581A1 (ru) | Везикулярные композиции | |
| MX381429B (es) | Tricostatina a (tsa) para usarse en el tratamiento del cáncer. |